Stay updated on PT2385 Tablets in Advanced RCC Clinical Trial
Sign up to get notified when there's something new on the PT2385 Tablets in Advanced RCC Clinical Trial page.

Latest updates to the PT2385 Tablets in Advanced RCC Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedUpdated the Locations section to include multiple state sites (CA, CO, CT, FL, GA, IL, IN, MD, MA, MI, NY, OH, PA, TN, TX, VA, WA, WI) and bumped the page revision to v3.3.3.SummaryDifference2%

- Check19 days agoNo Change Detected
- Check26 days agoNo Change Detected
- Check40 days agoChange DetectedA new note explains that publications are auto-filled from PubMed and may not be about the study, and the page revision now shows v3.3.2, replacing the previous PubMed wording. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check48 days agoChange DetectedThe government funding status disclaimer text was removed from the study record page. The disclaimer previously informing users about potential delays and updates is no longer displayed.SummaryDifference0.3%

- Check69 days agoChange DetectedAmendment 09 (Mar 29, 2024) transitions Part 2 from MK-3795 to belzutifan in combination with nivolumab or belzutifan alone. The study design and arm descriptions have been updated to reflect this change.SummaryDifference0.3%

- Check91 days agoChange DetectedSummary of changes: updated operating-status notice and a version bump to v3.2.0, replacing the previous v3.1.0.SummaryDifference2%

- Check98 days agoChange DetectedTerm naming updated from 'Clear cell renal carcinoma' to 'Clear cell carcinoma of kidney' with a version bump to v3.1.0.SummaryDifference0.2%

Stay in the know with updates to PT2385 Tablets in Advanced RCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PT2385 Tablets in Advanced RCC Clinical Trial page.